title: Intravitreal bevacizumab treatment of radiation maculopathy due to brachytherapy in choroidal melanoma.
authors.forename: Focke
authors.initials: F
authors.lastname: Ziemssen
authors.forename: Michael
authors.initials: M
authors.lastname: Voelker
authors.forename: Elke
authors.initials: E
authors.lastname: Altpeter
authors.forename: Karl U
authors.initials: KU
authors.lastname: Bartz-Schmidt
authors.forename: Faik
authors.initials: F
authors.lastname: Gelisken
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001918:Brachytherapy / Q000009:adverse effects*; D002830:Choroid Neoplasms / Q000532:radiotherapy*; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008297:Male; D008545:Melanoma / Q000532:radiotherapy*; D008875:Middle Aged; D011832:Radiation Injuries / Q000188:drug therapy* / Q000209:etiology; D012160:Retina / Q000528:radiation effects*; D012429:Ruthenium Radioisotopes / Q000009:adverse effects; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D012429:Ruthenium Radioisotopes; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab